Le programme scientifique de l’ISHEID 2022 sera disponible prochainement

MONDAY, MAY 17, 2021

LESSONS FROM COVID-19: PITFALLS AND PROMISE (In partnership with the EACS Young Investigators) / LES LEÇONS DE LA COVID-19 : PIÈGES ET PROMESSES (en partenariat avec les jeunes chercheurs de l’EACS)

17:30

Chairs: Christina PSOMAS, European Hospital, Marseille, France Annemarie WENSING, University Medical Center Utrecht, Netherlands Moderator: Tristan BARBER, Royal Free London NHS Foundation Trust, London, England


HIV and COVID-19 / VIH et COVID-19
Christoph SPINNER, Munich, Germany

Research pitfalls; what COVID has taught us / Les pièges de la recherche : ce que le COVID-19 nous apprend
Laura WATERS, London, England

HIV CURE / LA GUÉRISON DU VIH

18:45

Chairs: Sabine KINLOCH, Institute of Immunity & Transplantation, London, England Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada


Therapeutic simplification strategies in HIV infection and new ART strategies (2DR, triple regimen) / La simplification des stratégies thérapeutiques et les stratégies antirétrovirales chez les patients atteints par le VIH (2DR, triple regimen)
Jeff MURRY, Foster City, USA

Dual therapy against tritherapy: inflammation Vs toxicity / Les bithérapies contre les trithérapies : inflammation Vs toxicité
Christina PSOMAS, Marseille, France
Casper ROKX, Rotterdam, the Netherlands

BEST ORAL COMMUNICATIONS / MEILLEURES COMMUNICATIONS ORALES

20:00

Chairs: Guido POLI, Vita-Salute San Raffaele University, Milano, Italy Santiago MORENO, Hospital Ramón y Cajal, Madrid, Spain


O1. Impact of early antiretroviral therapy on tissue resident myeloid cells in the liver and lung of SIV-infected rhesus macaques
Authors: J. CLAIN, H. RABEZANAHARY, G. RACINE, G. BENMADID-LAKTOUT, O. ZGHIDI-ABOUZID, J. ESTAQUIER
Quebec University Hospital, Laval University, Research Center, Quebec - Canada

O2. Sexual satisfaction in women living with HIV. Are they the forgotten ones?
Authors: L. GONZÁLEZ RODRÍGUEZ1, J. BALIÑAS2, R. SCHULTZE3, L. LABAJO3, M.D.G. MUÑOZ3, Á. MENA2
1Obstetrics And Gynecology Service, Álvaro Cunqueiro University Hospital, Vigo - Spain
2Infectious Pathology Unit, A Coruña University Complex, A Coruña - Spain
3Infectious Pathology Unit, Álvaro Cunqueiro University Hospital, Vigo - Spain

O3. Influence of Hepatitis E virus genetic variability on the viral circulation between humans and environment
Authors: E. SCHVOERER1, C. HARTARD1, H. FENAUX1, A. DE ROUGEMONT2, E. LAUGEL1, S. BERGER1,J.P. BRONOWICKI3, I. BERTRAND4
1Nancy University Hospital, Laboratory of Virology, Vandœuvre-Lès-Nancy - France
2Dijon University Hospital, Laboratory of Virology, Dijon - France
3Nancy University Hospital, Hepato-Gastroenterology, Vandoeuvre Les Nancy - France
4 Lcpme (laboratoire De Chimie Physique Et Microbiologie Pour Les Matériaux Et L'environnement), Umr 7564Cnrs-Ul, Campus Santé Brabois, Vandoeuvre Les Nancy - France

O4. Effect of Metformin in non-diabetic people living with HIV: weight loss, decrease in inflammation and modification of the gut microbiota
Authors: S. ISNARD1, J. LIN1, T. VARIN2, A. MARETTE2, D. PLANAS3, C. VAN DER LEY4, P. ANCUTA3, J.P. ROUTY1
1Mcgill University Health Centre, Montreal - Canada
2Laval University, Québec - Canada
3 Montreal University, Montreal - Canada
4University Of Groningen, Groningen - Netherlands

O5. Extensive proteomic and transcriptomic changes quench the TCR/CD3 activation signal in latently HIV-1 infected T cells
Authors: E. CARLIN, B. GREER, A. DUVERGER, F. WAGNER, D. MOYLAN, A. DALECKI, S. SABBAJ, O. KUTSCH UAB, Birmingham - United States

DP1. Tracing the patterns of HIV-1 transmission among individuals with different diagnosis status in Greece
Authors: E-G. KOSTAKI1, S. LIMNAIOS1, S. PATRINOS2, D. CHATZIDIMITRIOU3, G. MAGIORKINIS1, L. SKOURA3, V. SYPSA1, A. HATZAKIS1, D. PARASKEVIS1
1Department Of Hygiene, Epidemiology And Medical Statistics, Medical School, National And Kapodistrian University Of Athens, Athens - Greece
2Hellenic Center For Diseases Control And Prevention, Marousi - Greece
3 National Aids Reference Center Of Northern Greece, Department Of Microbiology, Aristotle University Medical School, Thessaloniki - Greece

DP2. Identification of fast-growing HIV-1 transmission clusters in Spain and its potential application in Public Health
Authors: H. GIL, E. DELGADO, S. BENITO, M. SÁNCHEZ, J. CAÑADA, E. GARCÍA-BODAS, M.M. THOMSON,
Spanish group for the study of new HIV diagnoses
National Microbiology Centre. Carlos III Health Institute, Majadahonda - Spain

DP3. No impact of SARS-CoV-2 on the Activation Status of ART+HIV+ Patients
Authors: M. NIKOLOVA1, R. EMILOVA1, Y. TODOROVA1, N. YANCHEVA2, I. ALEXIEV3, R. GROZDEVA2, D. STRASHIMIROV2,N. KUYCHUKOVA2
1Nrl Of Immunology, National Centre Of Infectious And Parasitic Diseases, Sofia - Bulgaria
2Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases, Sofia - Bulgaria3Nrl Of HIV, National Center of Infectious and Parasitic Diseases, Sofia - Bulgaria

DP4. Factors associated with willingness to participate in end-of-life cure research: perspectives from People Living with HIV
Authors: D. LESSARD1, M. BILODEAU2, P. KEELER3, J.P. ROUTY4, E.A. COHEN5, K. DUBÉ6, B. LEBOUCHÉ1,C. COSTINIUK4
1Canadian Institutes Of Health Research Strategy For Patient-Oriented Research Mentorship Chair In Innovative Clinical Trials, Montreal - Canada
2Ontario Aids Network, Toronto - Canada
3Aids Community Care Montreal, Montreal - Canada
4Research Institute of the Mcgill University Health Centre, Montreal - Canada
5Montreal Institute of Clinical Research, Department of Microbiology, Infectiology and Immunology, Montreal University,Montreal - Canada
6Public Health Leadership Program, University Of North Carolina At Chapel Hill And Chapel Hill And Gilings School Of Global Public Health, Chapel Hill - USA

DP5. Fibrosis regression in HIV-HCV coinfected patients treated by DAAs
Authors: G. LAURICHESSE1, P. JAFFEUX2, A. MIRAND3, N. MROZEK1, M. VIDAL1, V. CORBIN1, H. LAURICHESSE1,C. JACOMET1
1Clermont-Ferrand University Hospital, Infectious Diseases, Clermont-Ferrand - France
2Clermont-Ferrand University Hospital, Statistics, Clermont-Ferrand - France
3Clermont-Ferrand University Hospital, Virology, Clermont-Ferrand - France

DP6. Differential Serotyping of HEV genotype 1 and 3
Authors: M. SHATA1, E. ABDEL-HAMEED1, S. ROUSTER1, H. HETTA2, K. SHERMAN3
1University of Cincinnati, Cincinnati - USA
2Department of Medical Microbiology and Immunology, Faculty of Medicine,Assiut University, Assiut - Egypt
3University of Cincinnati, Internal Medicine, Digestive Dis., Cincinnati - USA



TUESDAY, MAY 18, 2021

VACCINES / LES VACCINS

17:00

Moderator: Diana FINZI, National Institute of Health, Bethesda, USA Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada


Vaccines update for HIV and immunosuppressed patients / Calendrier vaccinal pour les PVVIH et les patients immunodéprimés
Anna-Maria GERETTI, London, England

Post-infection Vs post-vaccinal SARS-CoV-2 immunity: challenges and reality / Post-infection Vs l’immunité acquise grâce au vaccin : défi et réalité
Olivier SCHWARTZ, Paris, France

QUALITY OF LIFE MATTERS! TAILOR CARE TO OPTIMIZE IT IN PLWH
Symposium sponsored by MSD/ symposium parrainé par MSD

18:15

Moderator: Jonathan Schapiro, Sheba, ISR

Welcome and introduction
Jonathan Schapiro, Sheba, ISR

Future of NNRTIs: State of the ART of NNRTI resistance
Jonathan Schapiro, Sheba, ISR

Tailoring care for the body
Paddy Mallon, Dublin, IRL

Tailoring care for women with HIV
Karine Lacombe, Paris, FRA

Q&A

COMORBITIES AND MICROBIOTE / COMORBIDITÉS ET MICROBIOTE

19:30

Chairs: Jose Ignacio BERNARDINO, La Paz University Hospital, Madrid, Spain Christina PSOMAS, European Hospital, Marseille, France


The microbiome / Le microbiome
Sergio SERRANO VILLAR, Madrid, Spain

NASH and obesity and weight gain in hepatitis and HIV / La NASH chez les personnes atteintes par une hépatite ou par le VIH
Paddy MALLON, Dublin, Ireland

Role of hepatotropic viruses in the pathogenesis of cancer in PLWH / Le rôle des virus hépatotropes dans la pathogénèse du cancer chez les PVVIH
Alvaro MENA, Coruna, Spain

O6. Myocardial abnormailties in HIV: Insights from Cardiac Magnetic Resonacne Imaging (MRI)
Authors: G. MANMATHAN1, L. CHACKO2, R. MURKI2, T. KOTECHA2, C. LITTLE2, T. BARBER1,S. KINLOCH1, M. JOHNSON1, R. RAKHIT2
1Royal Free Hospital, London - United Kingdom
2University College London, London - United Kingdom

O7. Cardiomyopathy, pulmonary hypertension and myocarditis not as prevalent in well controlled
HIV: H-ART to Heart study
Authors: G. MANMATHAN, N. NGWU, J. JOHNSON, C. LITTLE, T. KOTECHA, M. JOHNSON, R. RAKHIT
Royal Free Hospital, London - United Kingdom

DP7. Nlrp3 inflammasome activation in peripheral blood leukocytes from HIV-infected patients and its contribution to chronic inflammation
Authors: V. NUNES CORDEIRO LEAL, E.C. DOS REIS, A. PONTILLO
University Of Sao Paulo, Sao Paulo - Brazil



WEDNESDAY, MAY 19, 2021

HOW TO END THE HIV PANDEMIC? / COMMENT ÉRADIQUER LA PANDÉMIE DE VIH ?

17:00

Chairs: Caroline SABIN, Royal Free Campus, London - England Christina PSOMAS, European Hospital, Marseille, France


London experience / L’expérience londonienne
Alison BROWN, London, England

Fast track cities, where are we? / Les fast-track cities : où en sommes-nous ?
Bertrand AUDOIN, Paris, France

BEYOND VIRAL SUPPRESSION, WHAT ARE THE CHALLENGES IN THE MANAGEMENT OF HIV INFECTION IN 2021?
Symposium sponsored by GILEAD/ symposium parrainé par GILEAD

18:15

Moderator: Christina Psomas

Inflammation and Immune markers
Christina Psomas, Montpellier, FRA

Sleep disorders and depression
Anne Moroy, Lille, FRA

Prevention and management of drug drug interactions
Olivier Robineau, Tourcoing, FRA

SARS-COV-2

19:30

Chairs: Valérie POURCHER, Hôpital de la Pitié-Salpêtrière, Paris, France Hervé TISSOT DUPONT, Aix-Marseille University, Marseille, France


Neurological complications of COVID-19, in acute disease and long-term / Les complications neurologiques de la COVID-19, dans les maladies aiguës et au long cours
Arvid EDÉN, Gothenburg, Sweden

Genetic determinants of COVID-19 disease severity / Les déterminants génétiques qui ont un impact sur la gravité de la COVID-19
Manuel CORPAS, Cambridge, England

DP8. Viral rebound (VR) 14 years after discontinuation of antiretroviral therapy (ART)
Authors: S. KINLOCH-DE LOES1, L. VANDEKERCKHOVE2, F. BURNS3, M. JOHNSON1
1Royal Free Hospital, London - United Kingdom
2University of Ghent, Ghent - Belgium
3Ucl, London - United Kingdom

DP9. Frailty phenotype is associated with antiretroviral exposure among older persons living with HIV
Authors: G. FELKER1, P. ENEL1, N. PETIT1, I. RAVAUX1, A. DARQUE1, F. RETORNAZ2
sup1Public University Hospital of Marseille, Marseille - France
2Department Of Public Health, Self-Perceived Health Assessment Research Unit Ea3279,Aix-Marseille University, Marseille - France

THURSDAY, MAY 20, 2021

CLIMATE AND SOCIO-POLITICAL CHANGES, HIV AND EPIDEMICS / CHANGEMENTS CLIMATIQUES ET SOCIO-POLITIQUES, VIH ET ÉPIDÉMIES

17:00

Chairs: Stephano VELLA, Superior Health Institute, Rome, Italy Ferdinand WIT, Academic Medical Center Amsterdam, Netherlands


HIV and global health in the era of coronavirus
Stefano VELLA, Rome, Italy

HTLV-1 has become a new STI
Carmen DE MENDOZA, Madrid, Spain

LONG-TERM VIROLOGICAL AND CLINICAL IMPACT OF DUAL THERAPY / IMPACT VIROLOGIQUE ET CLINIQUE LONG TERME DE LA BITHÉRAPIE
Symposium sponsored by VIIV HEALTHCARE/ symposium parrainé par VIIV HEALTHCARE

18:15

Moderator: Christine KATLAMA, Paris, FRA

Dual therapies: what are the impacts on HIV reservoirs? / Bithérapies : quels sont les impacts sur les réservoirs du VIH ?
Véronique Avettand-Fenoel. MCU-PH - UNIVERSITE PARIS , CHU Necker-Enfants Malades, Paris, FRA

What is the impact of long term dual therapy on bone, renal,inflammation and metabolics? / Quel est l'impact de la bithérapie à long terme sur l'os, le rein,l'inflammation et le métabolisme ?
Laura Waters, FRCP MD. Mortimer Market Centre, CNWL, London, UK

SEXUALLY TRANSMITTED INFECTIONS / LES INFECTIONS SEXUELLEMENT TRANSMISSIBLES

19:30

Chairs: Patricia ENEL, Aix-Marseille University, Marseille, France Patrick PHILIBERT, European Hospital, Marseille, France


Impact of COVID on sexual behaviour/risks/testing/ L'impact de la COVID sur les comportements/risques/essais sexuels
Cath MERCER, London, England

New challenges in STIs: M. Genitalium, XDR N.gonorrhoeae / Les nouveaux défis parmi les IST : M. Genitalium, XDR N.gonorrhoeae
Vicente SORIANO, Madrid, Spain

O8. Sexual Transmission of HTLV-1 and expanded spectrum of clinical manifestations
Authors: V. SORIANO1, J.M. RAMOS2, H. PINARGOTE2, C. DE MENDOZA3, A. SPANISHH T L V NETWORK3
1Unir Health Sciences School & Medical Center, Madrid - Spain
2General University Hospital & Miguel Hernandez University, Alicante - Spain
3Puerta De Hierro University Hospital & San Pablo University-Ceu, Madrid - Spain

DP10. HIV-2 in Spain - steadily increasing and new challenges
Authors: V. SORIANO1, T. CABEZAS2, E. CABALLERO3, A.B. LOZANO2, C. DE MENDOZA4
1Unir Health Sciences School & Medical Center, Madrid - Spain
2Hospital De Poniente, Almeria - Spain
3Hospital Vall D'hebron, Barcelona - Spain
4Puerta De Hierro Research Institute, Madrid - Spain